奥比他韦/帕立普韦/利托那韦+达沙布韦±利巴韦林用于治疗白俄罗斯共和国慢性丙型肝炎1型。
Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus.
作者信息
Danilau Dzmitry, Malich Nadzeya, Litvinchuk Dzmitry, Karpov Igor
机构信息
Belarusian State Medical University, Belarus.
出版信息
Clin Exp Hepatol. 2017 Sep;3(3):164-168. doi: 10.5114/ceh.2017.70281. Epub 2017 Sep 25.
AIM OF THE STUDY
Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype.
MATERIAL AND METHODS
The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment.
RESULTS
Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment. The SVR12 and SVR24 rate was 100% (27/27).
DISCUSSION
The results of the treatment were comparable to the results of pivotal, large-scale, randomized clinical trials. There were no serious adverse events during the treatment.
研究目的
本研究的目的是评估ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± 利巴韦林治疗1型慢性丙型肝炎的真实疗效。
材料与方法
根据纳入标准，该研究纳入了27例患者。在基线期和治疗期间对所有患者进行了主要实验室检查。
结果
通过测量治疗期间的SVR12和SVR24以及病毒载量来评估抗病毒治疗的疗效。SVR12和SVR24率为100%（27/27）。
讨论
治疗结果与关键的大规模随机临床试验结果相当。治疗期间未发生严重不良事件。
Zotero 插件